局限期小细胞肺癌同步每日一次与每日两次放化疗对比(CONVERT):一项开放标签、3期、随机、优效性试验
CONVERT研究在8个国家73个中心入组547例局限期小细胞肺癌患者,随机接受每日两次45 Gy(30次,每次1.5 Gy)或每日一次66 Gy(33次,每次2 Gy)同步放化疗。中位随访45个月,两组中位总生存30个月 vs 25个月(HR 1.18,95%CI 0.95-1.45,p=0.14),2年总生存56% vs 51%,差异未达统计学显著;作者结论认为每日两次放疗应继续被视为该情形的标准治疗。
要点
- 两组生存无显著差异:中位总生存每日两次组30个月 vs 每日一次组25个月,HR 1.18(95%CI 0.95-1.45),p=0.14。
- 2年总生存每日两次组56% vs 每日一次组51%,绝对差5.3%(95%CI -3.2%至13.7%)。
- 4级中性粒细胞减少每日两次组更常见:129例(49%)vs 101例(38%),p=0.05;两组3-4级放射性肺炎与食管炎无差异。
核心结论
- 在局限期小细胞肺癌患者中,每日两次与每日一次同步放化疗的生存结局无显著差异,两组毒性相似且低于预期。
- 由于该试验旨在证明每日一次放疗的优效性且未把握度证明等效性,作者认为每日两次放疗应继续被视为该情形的标准治疗。
研究设计与样本
- CONVERT为开放标签、3期、随机、优效性试验,入组年龄≥18岁、细胞学或组织学确诊的局限期小细胞肺癌、ECOG体能状态0-2分且肺功能足够的成人患者。
- 患者来自8个国家73个中心,2008年4月7日至2013年11月29日共547例随机分配至每日两次同步放化疗组(274例)或每日一次同步放化疗组(273例)。
- 随机采用最小化法并含随机成分,按机构、计划化疗周期数和体能状态分层;分组未设盲;主要终点为总生存,按改良意向性分析。
主要发现
- 中位随访45个月(IQR 35-58),中位总生存每日两次组30个月(95%CI 24-34)vs 每日一次组25个月(95%CI 21-31),每日一次组死亡HR 1.18(95%CI 0.95-1.45),p=0.14。
- 2年总生存每日两次组56%(95%CI 50-62)vs 每日一次组51%(95%CI 45-57),两组绝对差5.3%(95%CI -3.2%至13.7%)。
- 化疗毒性评估人群中,最常见的3-4级不良事件为中性粒细胞减少:每日两次组266例中197例(74%)vs 每日一次组263例中170例(65%)。
- 4级中性粒细胞减少每日两次组显著更多:129例(49%)vs 101例(38%),p=0.05;3-4级食管炎每日两次组254例中47例(19%)vs 每日一次组246例中47例(19%),p=0.85;3-4级放射性肺炎4例(3%)vs 4例(2%),p=0.70。
- 11例死于治疗相关原因,其中每日两次组3例、每日一次组8例。
关键数值与推荐
- 每日两次放疗方案:45 Gy,30次,每次1.5 Gy,共19天。
- 每日一次放疗方案:66 Gy,33次,每次2 Gy,共45天。
- 两组均于开始顺铂-依托泊苷化疗后第22天开始放疗,化疗为每3周一次、共4-6个周期。
- 每日一次组相对每日两次组死亡HR 1.18(95%CI 0.95-1.45),p=0.14;2年总生存绝对差5.3%(95%CI -3.2%至13.7%)。
- 4级中性粒细胞减少每日两次组129例(49%)vs 每日一次组101例(38%),p=0.05。
临床怎么用
- 原文结论认为,每日两次放疗应继续被视为局限期小细胞肺癌的标准治疗。
- 作者指出该试验旨在证明每日一次放疗优效且未把握度证明等效性,故生存无差异不能解释为每日一次方案可替代每日两次方案。
局限性
- 该试验旨在证明每日一次放疗的优效性,未把握度证明等效性。
- 4例患者(每日两次组1例、每日一次组3例)未返回病例报告表而失访,未纳入分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy schedule and dose remains controversial. The aim of this study was to establish a standard chemoradiotherapy treatment regimen in limited-stage small-cell lung cancer. METHODS: The CONVERT trial was an open-label, phase 3, randomised superiority trial. We enrolled adult patients (aged ≥18 years) who had cytologically or histologically confirmed limited-stage small-cell lung cancer, Eastern Cooperative Oncology Group performance status of 0-2, and adequate pulmonary function. Patients were recruited from 73 centres in eight countries. Patients were randomly assigned to receive either 45 Gy radiotherapy in 30 twice-daily fractions of 1·5 Gy over 19 days, or 66 Gy in 33 once-daily fractions of 2 Gy over 45 days, starting on day 22 after commencing cisplatin-etoposide chemotherapy (given as four to six cycles every 3 weeks in both groups). The allocation method used was minimisation with a random element, stratified by institution, planned number of chemotherapy cycles, and performance status. Treatment group assignments were not masked. The primary endpoint was overall survival, defined as time from randomisation until death from any cause, analysed by modified intention-to-treat. A 12% higher overall survival at 2 years in the once-daily group versus the twice-daily group was considered to be clinically significant to show superiority of the once-daily regimen. The study is registered with ClinicalTrials.gov (NCT00433563) and is currently in follow-up. FINDINGS: Between April 7, 2008, and Nov 29, 2013, 547 patients were enrolled and randomly assigned to receive twice-daily concurrent chemoradiotherapy (274 patients) or once-daily concurrent chemoradiotherapy (273 patients). Four patients (one in the twice-daily group and three in the once-daily group) did not return their case report forms and were lost to follow-up; these patients were not included in our analyses. At a median follow-up of 45 months (IQR 35-58), median overall survival was 30 months (95% CI 24-34) in the twice-daily group versus 25 months (21-31) in the once-daily group (hazard ratio for death in the once daily group 1·18 [95% CI 0·95-1·45]; p=0·14). 2-year overall survival was 56% (95% CI 50-62) in the twice-daily group and 51% (45-57) in the once-daily group (absolute difference between the treatment groups 5·3% [95% CI -3·2% to 13·7%]). The most common grade 3-4 adverse event in patients evaluated for chemotherapy toxicity was neutropenia (197 [74%] of 266 patients in the twice-daily group vs 170 [65%] of 263 in the once-daily group). Most toxicities were similar between the groups, except there was significantly more grade 4 neutropenia with twice-daily radiotherapy (129 [49%] vs 101 [38%]; p=0·05). In patients assessed for radiotherapy toxicity, was no difference in grade 3-4 oesophagitis between the groups (47 [19%] of 254 patients in the twice-daily group vs 47 [19%] of 246 in the once-daily group; p=0·85) and grade 3-4 radiation pneumonitis (4 [3%] of 254 vs 4 [2%] of 246; p=0·70). 11 patients died from treatment-related causes (three in the twice-daily group and eight in the once-daily group). INTERPRETATION: Survival outcomes did not differ between twice-daily and once-daily concurrent chemoradiotherapy in patients with limited-stage small-cell lung cancer, and toxicity was similar and lower than expected with both regimens. Since the trial was designed to show superiority of once-daily radiotherapy and was not powered to show equivalence, the implication is that twice-daily radiotherapy should continue to be considered the standard of care in this setting. FUNDING: Cancer Research UK (Clinical Trials Awards and Advisory Committee), French Ministry of Health, Canadian Cancer Society Research Institute, European Organisation for Research and Treatment of Cancer (Cancer Research Fund, Lung Cancer, and Radiation Oncology Groups).
引用
- Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017. PMID: 28642008. doi:10.1016/S1470-2045(17)30318-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。